"J&J's $2 Billion Acquisition of Ambrx Biopharma Signals Major Advances in Cancer Treatment"

Johnson & Johnson and Merck kick off a major U.S. healthcare conference by announcing plans to acquire cancer therapy developers, with combined deals worth over $6 billion, signaling a strong start for M&A in 2024. J&J is set to buy Ambrx Biopharma for $2 billion to gain targeted cancer therapies, while Merck plans to acquire Harpoon Therapeutics for about $680 million to access early-stage immunotherapies for lung cancer and multiple myeloma. Additionally, medical device maker Boston Scientific is entering the market with a $3.7 billion deal for Axonics Inc, reflecting a return to business as usual in the pharmaceutical industry after the challenges of 2023.